Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 51 results.
User Information
Export Records
  1. 1.   Treatment with a JAK1/2 inhibitor ameliorates murine autoimmune cholangitis induced by IFN overexpression
  2. Shao, Tihong; Leung, Patrick S C; Zhang, Weici; Tsuneyama, Koichi; Ridgway, William M; Young,Howard; Shuai, Zongwen; Ansari, Aftab A; Gershwin, M Eric
  3. Cellular & Molecular Immunology. 2022, Aug 30;
  1. 2.   ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1
  2. Su, Wenjing; Mukherjee, Radha; Yaeger, Rona; Son, Jieun; Xu, Jianing; Na, Na; Merna Timaul, Neilawattie; Hechtman, Jaclyn; Paroder, Viktoriya; Lin, Mika; Mattar, Marissa; Qiu, Juan; Chang, Qing; Zhao, Huiyong; Zhang, Jonathan; Little, Megan; Adachi, Yuta; Han, Sae-Won; Taylor, Barry S; Ebi, Hiromichi; Abdel-Wahab, Omar; de Stanchina, Elisa; Rudin, Charles M; Jänne, Pasi A; McCormick, Frank; Yao, Zhan; Rosen, Neal
  3. Molecular Cell. 2022, May 14;
  1. 3.   Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors
  2. Takebe, Naoko; Naqash, Abdul Rafeh; Coyne, Geraldine O'Sullivan; Kummar, Shivaani; Do, Khanh; Bruns, Ashley; Juwara,Lamin; Zlott, Jennifer; Rubinstein, Larry; Piekarz, Richard; Sharon, Elad; Streicher, Howard; Mittra, Arjun; Miller, Sarah B.; Ji,Jay; Wilsker,Deborah; Kinders,Robert; Parchment,Ralph; Chen,Li; Chang,Ting-Chia; Das,Biswajit; Mugundu, Ganesh; Doroshow, James H.; Chen, Alice P.
  3. CLINICAL CANCER RESEARCH. 2021, Apr 16; 27(14): 3834-3844.
  1. 4.   A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components
  2. Nilsson, Monique B.; Sun, Huiying; Robichaux, Jacqulyne; Pfeifer, Matthias; McDermott, Ultan; Travers, Jon; Diao, Lixia; Xi, Yuanxin; Tong, Pan; Shen, Li; Hofstad, Mia; Kawakami, Masanori; Le, Xiuning; Liu, Xi; Fan, Youhong; Poteete, Alissa; Hu, Limei; Negrao, Marcelo; Tran, Hai; Dmitrovsky, Ethan; Peng, David; Gibbons, Don L.; Wang, Jing; Heymach, John
  3. SCIENCE TRANSLATIONAL MEDICINE. 2020, SEP 2; 12(559): pii: aaz4589.
  1. 5.   Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor
  2. Helman, Elena; Nguyen, Minh; Karlovich, Chris; Despain, Darrin; Choquette, A Karin; Spira, Alexander I; Yu, Helena A; Camidge, D Ross; Harding, Thomas C; Lanman, Richard B; Simmons, Andrew D
  3. Clinical lung cancer. 2018, Nov; 19(6): 518-530.e7.
  1. 6.   Pregnancy on vandetanib in metastatic medullary thyroid carcinoma associated with multiple endocrine neoplasia type 2B
  2. Thomas, Nicholas; Glod, John; Derse-Anthony, Claudia; Baple, Emma L; Obsborne, Nigel; Sturley, Rachel; Vaidya, Bijay; Newbold, Kate; Brooke, Antonia
  3. Clinical endocrinology. 2018, May; (5): 754-756.
  1. 7.   How to Achieve Better Results Using PASS-Based Virtual Screening: Case Study for Kinase Inhibitors
  2. Pogodin, Pavel V; Lagunin, Alexey A; Rudik, Anastasia V; Filimonov, Dmitry A; Druzhilovskiy, Dmitry S; Nicklaus, Marc; Poroikov, Vladimir V
  3. Frontiers in chemistry. 2018, Apr 26; 6: 133.
  1. 8.   Engaging Anaphase Catastrophe Mechanisms to Eradicate Aneuploid Cancers
  2. Kawakami, Masanori; Mustachio, Lisa Maria; Liu, Xi; Dmitrovsky, Ethan
  3. Molecular Cancer Therapeutics. 2018, Apr; 17(4): 724-731.
  1. 9.   Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo [3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple -acting angiokinase inhibition as antitumor agents
  2. Pavana, Roheeth Kumar; Choudhary, Shruti; Bastian, Anja; Ihnat, Michael A.; Bai, Ruoli; Hamel, Ernest; Gangjee, Aleem
  3. BIOORGANIC & MEDICINAL CHEMISTRY. 2017, Jan 15; 25(2): 545-556.
  1. 10.   The importance of Raf dimerization in cell signaling
  2. Freeman, A. K.; Ritt, D. A.; Morrison, D. K.
  3. Small GTPases. 2013, Jul-Sep; 4(3): 180-5.
  1. 11.   Vascular endothelial growth factor receptor 2 inhibition in-vivo affects tumor vasculature in a tumor type-dependent way and downregulates vascular endothelial growth factor receptor 2 protein without a prominent role for miR-296
  2. Langenkamp, E.; Zwiers, P. J.; Moorlag, H. E.; Leenders, W. P.; Croix, B. S.; Molema, G.
  3. Anti-Cancer Drugs. 2012, Feb; 23(2): 161-172.
  1. 12.   Structural characterization of inhibitor complexes with checkpoint kinase 2 (Chk2), a drug target for cancer therapy
  2. Lountos, G. T.; Jobson, A. G.; Tropea, J. E.; Self, C. R.; Zhang, G. T.; Pommier, Y.; Shoemaker, R. H.; Waugh, D. S.
  3. Journal of Structural Biology. 2011, Dec; 176(3): 292-301.
  1. 13.   X-ray structures of checkpoint kinase 2 in complex with inhibitors that target its gatekeeper-dependent hydrophobic pocket
  2. Lountos, G. T.; Jobson, A. G.; Tropea, J. E.; Self, C. R.; Zhang, G. T.; Pommier, Y.; Shoemaker, R. H.; Waugh, D. S.
  3. Febs Letters. 2011, Oct; 585(20): 3245-3249.
  1. 14.   Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas
  2. Kummar, S.; Gutierrez, M. E.; Chen, A.; Turkbey, I. B.; Allen, D.; Horneffer, Y. R.; Juwara, L.; Cao, L.; Yu, Y. K.; Kim, Y. S.; Trepel, J.; Chen, H.; Choyke, P.; Melillo, G.; Murgo, A. J.; Collins, J.; Doroshow, J. H.
  3. European Journal of Cancer. 2011, May; 47(7): 997-1005.
  1. 15.   Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production
  2. Zhang, S. L.; Readinger, J. A.; DuBois, W.; Janka-Junttila, M.; Robinson, R.; Pruitt, M.; Bliskovsky, V.; Wu, J. Z.; Sakakibara, K.; Patel, J.; Parent, C. A.; Tessarollo, L.; Schwartzberg, P. L.; Mock, B. A.
  3. Blood. 2011, Jan; 117(4): 1228-1238.
  1. 16.   Recent Development of Cyclic Amide (Pyridone/Lactam) Moiety Containing Heterocycles as Protein Kinase Inhibitors
  2. Wei, L. Y.; Malhotra, S. V.
  3. Current Medicinal Chemistry. 2010, Jan; 17(3): 234-253.
  1. 17.   Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice
  2. Gardner, E. R.; Smith, N. F.; Figg, W. D.; Sparreboom, A.
  3. Journal of experimental & clinical cancer research : CR. 2009 28: 99.
  1. 18.   Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras
  2. Lauchle, J. O.; Kim, D.; Le, D. T.; Akagi, K.; Crone, M.; Krisman, K.; Warner, K.; Bonifas, J. M.; Li, Q.; Coakley, K. M.; Diaz-Flores, E.; Gorman, M.; Przybranowski, S.; Tran, M.; Kogan, S. C.; Roose, J. P.; Copeland, N. G.; Jenkins, N. A.
  3. Nature. 2009 461(7262): 411-U110.
  1. 19.   Preparation of orthogonally protected (2S,3R)-2-amino-3-methyl-4-phosphonobutyric acid (Pmab) as a phosphatase-stable phosphothreonine mimetic and its use in the synthesis of polo-box domain-binding peptides
  2. Liu, F.; Park, J. E.; Lee, K. S.; Burke, T. R.
  3. Tetrahedron. 2009 65(47): 9673-9679.
  1. 20.   Hematopoiesis and thymic apoptosis are not affected by the loss of Cdk2
  2. Berthet, C.; Rodriguez-Galan, M. C.; Hodge, D. L.; Gooya, J.; Pascal, V.; Young, H. A.; Keller, J.; Bosselut, R.; Kaldis, P.
  3. Molecular and Cellular Biology. 2007, Jul; 27(14): 5079-5089.
  1. 21.   Transgenic expression of human thymidylate synthase accelerates the development of hyperplasia and tumors in the endocrine pancreas
  2. Chen, M.; Rahman, L.; Voeller, D.; Kastanos, E.; Yang, S. X.; Feigenbaum, L.; Allegra, C.; Kaye, F. J.; Steeg, P.; Zajac-Kaye, M.
  3. Oncogene. 2007, Jul; 26(33): 4817-4824.
  1. 22.   Natural products active in aberrant c-Kit signaling
  2. Henrich, C. J.; Goncharova, E. I.; Wilson, J. A.; Gardella, R. S.; Johnson, T. R.; McMahon, J. B.; Takada, K.; Bokesch, H. R.; Gustafson, K. R.
  3. Chemical Biology & Drug Design. 2007, May; 69(5): 321-330.
  1. 23.   Utilization of achiral alkenyl amines for the preparation of high affinity Grb2 SH2 domain-binding macrocycles by ring-closing metathesis
  2. Liu, F.; Worthy, K. M.; Bindu, L.; Giubellino, A.; Bottaro, D. P.; Fisher, R. J.; Burke, T. R.
  3. Organic & Biomolecular Chemistry. 2007 5(2): 367-372.
  1. 24.   Another piece of the p27(Kip1) puzzle
  2. Kaldis, P.
  3. Cell. 2007, Jan; 128(2): 241-244.
  1. 25.   Dependence of cisplatin-induced cell death in vitro and in vivo on cyclin-dependent kinase 2
  2. Price, P. M.; Yu, F.; Kaldis, P.; Aleem, E.; Nowak, G.; Safirstein, R. L.; Megyesi, J.
  3. Journal of the American Society of Nephrology. 2006, Sep; 17(9): 2434-2442.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel